SARS-CoV-2 infection: NLRP3 inflammasome as plausible target to prevent cardiopulmonary complications?
Betacoronavirus
/ isolation & purification
COVID-19
Cardiovascular Diseases
/ prevention & control
Clinical Trials as Topic
Coronavirus Infections
/ diagnosis
Cytokines
/ metabolism
Humans
Inflammasomes
/ metabolism
Myocarditis
/ prevention & control
NLR Family, Pyrin Domain-Containing 3 Protein
/ antagonists & inhibitors
Nitriles
/ therapeutic use
Pandemics
Pneumonia, Viral
/ diagnosis
Prognosis
SARS-CoV-2
Venous Thromboembolism
/ prevention & control
ortho-Aminobenzoates
/ therapeutic use
Journal
European review for medical and pharmacological sciences
ISSN: 2284-0729
Titre abrégé: Eur Rev Med Pharmacol Sci
Pays: Italy
ID NLM: 9717360
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
entrez:
23
9
2020
pubmed:
24
9
2020
medline:
2
10
2020
Statut:
ppublish
Résumé
NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) inflammasome has recently become an intriguing target of several chronic and viral diseases. Here, we argue that targeting NLRP3 inflammasome could be a strategy to prevent cardiovascular outcomes [fulminant myocarditis, heart failure, venous thromboembolism (VTE)] and acute respiratory distress syndrome (ARDS) in patients with SARS-CoV-2 infection. We discuss the rationale for NLRP3 targeting in clinical trials as an effective therapeutic strategy aimed to improve prognosis of COVID-19, analyzing the potential of two therapeutic options (tranilast and OLT1177) currently available in clinical practice.
Identifiants
pubmed: 32965010
doi: 10.26355/eurrev_202009_22867
pii:
doi:
Substances chimiques
Cytokines
0
Inflammasomes
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Nitriles
0
ortho-Aminobenzoates
0
dapansutrile
2Z03364G96
tranilast
HVF50SMY6E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM